Last reviewed · How we verify
Ovitrelle ( Hcg 250 mcg)
Ovitrelle is a recombinant human chorionic gonadotropin (hCG) that mimics the natural hormone to trigger final oocyte maturation and ovulation in assisted reproductive cycles.
Ovitrelle is a recombinant human chorionic gonadotropin (hCG) that mimics the natural hormone to trigger final oocyte maturation and ovulation in assisted reproductive cycles. Used for Final oocyte maturation and ovulation induction in assisted reproductive technology (ART) cycles, Ovulation triggering in controlled ovarian hyperstimulation for in vitro fertilization (IVF).
At a glance
| Generic name | Ovitrelle ( Hcg 250 mcg) |
|---|---|
| Sponsor | Fundacion Clinic per a la Recerca Biomédica |
| Drug class | Gonadotropin; recombinant human chorionic gonadotropin (rhCG) |
| Target | Luteinizing hormone receptor (LH receptor) |
| Modality | Small molecule |
| Therapeutic area | Reproductive Medicine / Fertility |
| Phase | FDA-approved |
Mechanism of action
hCG binds to luteinizing hormone (LH) receptors on ovarian cells, inducing the final stages of meiosis I completion and triggering the release of a mature egg from the ovarian follicle. This synthetic hCG is used as a substitute for the natural LH surge that normally occurs mid-cycle, allowing precise timing of ovulation in fertility treatment protocols.
Approved indications
- Final oocyte maturation and ovulation induction in assisted reproductive technology (ART) cycles
- Ovulation triggering in controlled ovarian hyperstimulation for in vitro fertilization (IVF)
Common side effects
- Ovarian hyperstimulation syndrome (OHSS)
- Injection site reactions (pain, erythema, bruising)
- Headache
- Abdominal pain or discomfort
- Nausea
Key clinical trials
- FET-LET-2x2: Clinical Pregnancy Rates After Frozen Embryo Transfer in Natural and Modified Natural Cycles (NA)
- Letrozole-stimulated Cycle Strategy Versus Artificial Cycle Strategy (LETSACT) (NA)
- Is There a Need for Luteal Support in Modified Natural Cycle Frozen Embryo Transfer Cycles (PHASE4)
- Impact of the Presence of the Corpus Luteum on Pregnancies Obtained Through Frozen Embryo Transfer(FET) (PHASE4)
- Follicle Size and Oocyte Development (NA)
- IVF Treatment in Women With Immature Oocytes in Previous Cycle (NA)
- Comparison of Triggers in Double Ovarian Stimulation (DuoStim). (PHASE4)
- PERgoveriS In Stratified Treatment for Assisted Reproductive Technique (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ovitrelle ( Hcg 250 mcg) CI brief — competitive landscape report
- Ovitrelle ( Hcg 250 mcg) updates RSS · CI watch RSS
- Fundacion Clinic per a la Recerca Biomédica portfolio CI